(Q51640753)

8 April 2018

title

Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials. (English)

1 reference

8 April 2018

main subject

phase I clinical trial

0 references

phase II clinical trial

0 references

author

Patrick Devos

4

1 reference

8 April 2018

Nicolas Penel

object named as

Nicolas Penel

1

0 references

author name string

Alain Duhamel

2

1 reference

8 April 2018

Antoine Adenis

3

1 reference

8 April 2018

Nicolas Isambert

5

1 reference

8 April 2018

Stéphanie Clisant

6

1 reference

8 April 2018

Jacques Bonneterre

7

1 reference

8 April 2018

publication date

4 November 2010

1 reference

8 April 2018

Investigational New Drugs

published in

1 reference

8 April 2018

volume

30

1 reference

8 April 2018

issue

2

1 reference

8 April 2018

page(s)

653-661

1 reference

8 April 2018

Phase I clinical trial design in cancer drug development

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Methodology of clinical trials with new molecular-targeted agents: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Continual reassessment method: a practical design for phase 1 clinical trials in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Continual reassessment method: a likelihood approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Pharmacologically guided phase I clinical trials based upon preclinical drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Risks and benefits associated with novel phase 1 oncology trial designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Molecularly targeted oncology therapeutics and prolongation of the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Choice of starting dose and escalation for phase I studies of antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9574-4

Dose selection in phase I studies: why we should always go for the top

21 January 2018

1 reference

12 December 2020

Dose escalation trial designs based on a molecularly targeted endpoint

1 reference

12 December 2020

Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for phase I clinical trials

1 reference

12 December 2020

Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials

1 reference

12 December 2020

Accelerated titration designs for phase I clinical trials in oncology

1 reference

12 December 2020

Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities.

1 reference

12 December 2020

Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)

1 reference

12 December 2020

10.1007/S10637-010-9574-4

Identifiers

DOI

1 reference

8 April 2018

1 reference

8 April 2018